Recent advances in combination of immunotherapy and chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
R Wang, S Liu, B Chen, M Xi - Cancers, 2022 - mdpi.com
Simple Summary Neoadjuvant chemoradiotherapy (CRT), followed by surgery or definitive
CRT, is the standard treatment for locally advanced esophageal squamous cell carcinoma …
CRT, is the standard treatment for locally advanced esophageal squamous cell carcinoma …
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
T Jiang, P Wang, J Zhang, Y Zhao, J Zhou… - … and Targeted Therapy, 2021 - nature.com
This multicenter phase-II trial aimed to investigate the efficacy, safety, and predictive
biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with …
biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with …
IL-1RAP, a key therapeutic target in cancer
J Frenay, PS Bellaye, A Oudot, A Helbling… - International Journal of …, 2022 - mdpi.com
Cancer is a major cause of death worldwide and especially in high-and upper-middle-
income countries. Despite recent progress in cancer therapies, such as chimeric antigen …
income countries. Despite recent progress in cancer therapies, such as chimeric antigen …
Perioperative systemic treatment for muscle-invasive bladder cancer: current evidence and future perspectives
IH Kim, HJ Lee - International Journal of Molecular Sciences, 2021 - mdpi.com
Radical cystectomy is the primary treatment for muscle-invasive bladder cancer; however,
approximately 50% of patients develop metastatic disease within 2 years of diagnosis, which …
approximately 50% of patients develop metastatic disease within 2 years of diagnosis, which …
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade
L Nazerai, SC Willis, P Yankilevich, L Di Leo… - …, 2023 - Taylor & Francis
Immune-checkpoint inhibitors (ICI) are highly effective in reinvigorating T cells to attack
cancer. Nevertheless, a large subset of patients fails to benefit from ICI, partly due to lack of …
cancer. Nevertheless, a large subset of patients fails to benefit from ICI, partly due to lack of …
PD-1 cellular nanovesicles carrying gemcitabine to inhibit the proliferation of triple negative breast cancer cell
H Zha, Z Xu, X Xu, X Lu, P Shi, Y Xiao, HI Tsai, D Su… - Pharmaceutics, 2022 - mdpi.com
PD-1 inhibitor Keytruda combined with chemotherapy for Triple-negative breast cancer
(TNBC) has been approved for FDA, successfully representing the combination therapy of …
(TNBC) has been approved for FDA, successfully representing the combination therapy of …
Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer
T Jiang, J Chen, H Wang, F Wu, X Chen… - Chinese Medical …, 2024 - journals.lww.com
Background: Programmed death 1 (PD-1) blockade plus chemotherapy has become the
new first-line standard of care for patients with advanced non-small-cell lung cancer …
new first-line standard of care for patients with advanced non-small-cell lung cancer …
P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy
AC Sarti, V Vultaggio-Poma, F Di Virgilio - Purinergic Signalling, 2021 - Springer
Alba Clara Sarti is currently a post-doctoral researcher at the Department of Medical
Sciences and a trainee in the Postgraduate School in Clinical Pathology and Clinical …
Sciences and a trainee in the Postgraduate School in Clinical Pathology and Clinical …
Efficacy and safety of PD‑1 inhibitor plus antiangiogenic treatment in patients with unresectable biliary tract cancer: A multicenter retrospective study
Z Wu, X Zhu, X Zhong, Y Wang… - Experimental and …, 2023 - spandidos-publications.com
Immunotherapy and antiangiogenic therapy have shown promising clinical activity in
patients with advanced biliary tract cancer (BTC) in clinical trials. As the combination of …
patients with advanced biliary tract cancer (BTC) in clinical trials. As the combination of …
Neoadjuvant immune checkpoint inhibitor treatment+ chemotherapy (vs. chemotherapy alone) for locally advanced non‑small cell lung cancer: A retrospective cohort …
Y Yang, Z Liu - Oncology Letters, 2023 - spandidos-publications.com
Neoadjuvant immune checkpoint inhibitor (ICI) treatment+ chemotherapy has been used for
locally advanced non‑small cell lung cancer (NSCLC); however, evidence regarding the …
locally advanced non‑small cell lung cancer (NSCLC); however, evidence regarding the …